The LEADERS FREE trial concluded that the polymer free drug-coated BioFreedom TM stent appeared to be both safer and more effective than bare-metal stents (BMS) with an ISR rate comparable to traditional DES without the need for prolonged DAPT. We implanted 45 BioFreedom TM stents in 34 patients over a 4-month period. 4 patients represented early (106-238 days after the implant procedure) with angina symptoms and severe ISR was detected in all patients. The rate of severe and early ISR detected in our patient population of 11.8% is comparable to that of traditional BMS. Further studies are warranted.
Introduction
The LEADERS FREE trial concluded that the polymer free drugcoated BioFreedom TM stent (DCS) appeared to be both safer and more effective than bare-metal stents (BMS) making it an interesting option in patients at high risk of bleeding in view of the shorter duration of dual antiplatelet therapy required. 1 The LEADERS trial was sponsored by Biosensors Europe (Morges, Switzerland). The reported clinically-driven target lesion revascularization rate at 1 year was only 5.1% for the DCS compared to 9.8% for the BMS. 1 The higher rate of in-stent restenosis (ISR) is one of the major disadvantages of BMS compared to drug-eluting stents (DES) but the LEADERS FREE trial for the first time showed an ISR rate for a stent that was comparable to traditional DES but did not require 12 months of dual antiplatelet therapy.
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Methods
The study is a small case series comprising a review of patients who were implanted with BioFreedom TM stents over a 4-month period from 29.04.2015 until 29.08.2015. On May 1st 2016, we retrospectively reviewed all patients that were implanted with a Biofreedom stent during that 4-month period. We analysed our angiogram database, whether patients underwent further angioplasty procedures following the Biofreedom implant. All angiograms were reviewed. Patients who did not undergo additional angioplasties were called up and questioned about the presence of ischaemic symptoms or whether the patient underwent procedures elsewhere.
Results

45
BioFreedom TM stents were implanted in 34 patients during the study period. The mean follow-up period was 322 days (minimum 247 days; maximum 368 days). We found, that 4 patients had to be re-studied when they presented with angina, an average of 186 days after the index procedure (106-238 days). In addition, early but asymptomatic ISR was noted in an additional patient during a staged procedure 36 days after implantation. All patients with severe ISR were of Indian ethnicity and diabetics. All other patients denied ischaemic symptoms when followed up. None of the patients underwent angiography in other hospitals. 1 patient had died due to a haematological condition. Patient characteristics and description of the procedures performed are outlined in Tables 1 and 2 , respectively. By just focusing on the 4 patients with severe ISR relatively early after stent implantation, we have to report a rate of severe ISR requiring re-intervention of 11.8%. The ISR seems to occur very early and appears to be aggressive. All 4 patients described had almost subtotal occlusion of their stents. Coronary angiogram images illustrating the initial stenosis and the result of the Biofreedom stenting procedure ("index procedure") and the observed ISR during relook angiogram are shown in Fig. 1 .
Discussion
The superiority of drug-eluting stents (DES) over bare-metal stents with regards to restenosis and cardiovascular outcome is well proven. 2, 3, 6 The only remaining advantage of bare metal stents is the shorter dual anti-platelet therapy (DAPT) duration; an important issue for patients at high bleeding risk or patients with the need to undergo non-cardiac surgery. 7, 8 Prior to BioFreedom TM , BMS were often preferred in these situations. 9 The polymer coating of a classic DES serves to attach and release the anti-inflammatory and antiproliferative drug in a sustained way. However, because of concerns that the polymer ISR -in-stent restenosis; CAD -coronary artery disease; STEMI -ST elevation myocardial infarction; NSTEMI -non-ST elevation myocardial infarction; DAPT -dual antiplatelet therapy. regime. Data from the LEADERS FREE trial seems to support this theory with a reported TVR rate of only 5.1% at 1 year. 1 Our observations were however very different. It appears that the absence of polymeric coating with a more rapid and less sustained drug release results in reduced therapeutic efficacy. Interventional cardiologists are familiar with ISR in BMS, however, the restenotic process in BMS seems to be gradual, slowly over time occurring and not aggressive as in the cases described here. We hypothesise that the micro-structured stent surface could exert negative effects onto the vessel wall resulting in early and severe ISR. Our study has limitations. Most notably, the number of patients is relatively small and not all procedures were done under IVUS guidance. Although stent under-sizing can never be fully ruled out without IVUS guidance, this possibility seems unlikely to fully explain the high rate of ISR observed in our study population. Therefore, we feel that post marketing real-world data collection at a larger scale is essential to investigate this potentially serious problem.
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